You are here: Industry Insights > Erelzi

News List

US Supreme Court Denies Sandoz Petition to Review Biosimilar Erelzi® Case americanpharmaceuticalreview
May 19, 2021
Sandoz has announced that the US Supreme Court has denied its petition to review the Federal Circuit’s July 2020 decision concerning the Sandoz biosimilar Erelzi® (etanercept-szzs) for reference medicine Enbrel®* (etanercept).
Federal Circuit Rules Upholds Lower Court Ruling in Biosimilar Erelzi Case americanpharmaceuticalreview
July 13, 2020
Sandoz, a Novartis division, announced the US Court of Appeals for the Federal District has ruled against Sandoz in patent litigation concerning the Sandoz biosimilar Erelzi® (etanercept-szzs) for reference medicine Enbrel® (etanercept).
Amgen wins court patent ruling over Sandoz biosimilar europeanpharmaceuticalreview
August 14, 2019
The US District Court has decided in favour of Amgen’s Enbrel, ruling over Sandoz’s Erelzi in a patent conflict.
Sandoz Canada receives Health Canada approval for Erelzi (etanercept) in the Treatment of Psoriatic Arthritis (PsA) in Adult Patients firstwordpharma
January 22, 2019
Erelzi is the only etanercept biosimilar to be indicated for reducing the signs and symptoms of psoriatic arthritis (PsA) in adult patients.
Sandoz’s Erelzi available for multiple inflammatory disease treatment in Canada pharmaceutical-technology
August 23, 2017
Novartis division Sandoz has made its Erelzi (etanercept) therapy available for the treatment of multiple inflammatory diseases for patients in Canada.
Sandoz receives EU approval for Erelzi (biosimilar etanercept) europeanpharmaceuticalreview
July 03, 2017
The European Commission (EC) has approved Sandoz’ (a Novartis division) Erelzi (biosimilar etanercept) for use in Europe, to treat inflammatory diseases…